Sanofi S.A.
French multinational pharmaceutical and healthcare company headquartered in Paris, engaged in research, development, manufacturing, and marketing of pharmaceuticals across therapeutic areas including cardiovascular, diabetes, oncology, and vaccines.
Clinical Trials
1571
99 active
Approvals
74
Total approvals
Agencies
1
Regulatory bodies
Founded
1973
Unknown
3
0.2%
Completed
1199
76.3%
Enrolling By Invitation
5
0.3%
Not yet recruiting
8
0.5%
No Longer Available
1
0.1%
Terminated
175
11.1%
Recruiting
78
5.0%
Suspended
1
0.1%
Approved For Marketing
1
0.1%
Available
1
0.1%
Withdrawn
13
0.8%
Active, not recruiting
86
5.5%
- Sanofi inaugurated the Charles Best Building in Toronto, a C$925 million influenza vaccine manufacturing facility that is the largest biomanufacturing investment in Canadian history. - The facility will produce Fluzone High-Dose, Sanofi's influenza vaccine containing four times the antigen of standard-dose vaccines and indicated for adults 65 and older. - Production is expected to begin in early 2027, pending regulatory approval, in preparation for the 2027-28 influenza season, with about 300 skilled jobs created. - The investment includes C$415 million from the Government of Canada and C$55 million from the Government of Ontario, and adds end-to-end manufacturing capacity to Sanofi's Toronto campus.
- Santa Ana Bio has dosed the first cohort in a first-in-human Phase 1 trial of SAB01, a bispecific antibody that co-engages KIT and Siglec-6 to selectively deplete mast cells. - The randomized, double-blind, placebo-controlled single ascending dose study (NCT07815561) evaluates subcutaneous and intravenous SAB01 in healthy adults, with primary objectives of safety, pharmacokinetics, and pharmacodynamics. - SAB01 is designed to uncouple mast cell depletion from broad KIT inhibition, potentially avoiding toxicities such as hematopoietic stem cell and melanocyte effects seen with existing KIT-targeted antibodies. - The Phase 1 start marks Santa Ana Bio's first entry into the clinic, while its CD40-targeted glucocorticoid antibody-drug conjugate SAB05 advances through IND-enabling studies toward a 2027 clinic entry.
- Sanofi and Cheplapharm announced a strategic partnership under which Cheplapharm would take over 20 mature medicines and three manufacturing sites worldwide. - Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration between the two companies that began in 2014. - The divested portfolio includes Lovenox/Clexane (enoxaparin), excluding the US, with commercial transfer planned to begin in the first quarter of 2027. - The transaction is expected to be fully completed by the third quarter of 2027, subject to employee consultation procedures, regulatory approvals and customary closing conditions.
- The FDA has completed its IND review period for IPN60330, the first MAIT cell engager, clearing Ipsen to begin a Phase 1 trial in the United States. - IPN60330 is a bispecific antibody built on Biomunex's BiXAb platform that engages MAIT cells and the clinically validated GPC3 tumor antigen. - The milestone triggers a payment under the November 2024 Ipsen-Biomunex global licensing deal, where Biomunex is eligible for up to $610 million plus royalties. - MAIT engagers may offer a broader therapeutic window than classical pan-T cell engagers, which activate all T cells and can cause cytokine release syndrome.
- Sanofi and USA Pickleball have launched 'Serve Up Protection,' a campaign to educate older adults about COVID-19 prevention and the FDA-approved NUVAXOVID vaccine. - NUVAXOVID is a protein-based, non-mRNA vaccine that entered the market more than a year after Pfizer's and Moderna's mRNA vaccines, leaving it with a small share of doses administered. - Concern about side effects was the top reason US adults 50 and older skipped COVID-19 vaccination, cited by 26% in a January University of Michigan poll. - Sanofi is positioning NUVAXOVID's generally milder short-term side-effect profile, supported by two pivotal phase 3 studies, as an answer to older adults' vaccination hesitation.
- AstraZeneca's IL-33 inhibitor tozorakimab reduced moderate-to-severe COPD exacerbations by 29% in OBERON and 34% in TITANIA among former smokers versus placebo. - Across more than 2,300 randomized patients, exacerbation reductions reached roughly 30% and 29% in the overall trial populations including current smokers. - Benefit extended across blood eosinophil counts, including a 23% reduction below 150 cells/microliter, a subgroup where COPD biologics have historically underperformed. - The FDA accepted the biologics licence application under Priority Review with a PDUFA date expected in Q1 2027, while EU and China reviews are also underway.
- The ISS National Laboratory has surpassed 1,000 sponsored payloads delivered to the orbiting laboratory since August 2011, a milestone reached during NASA's Northrop Grumman Commercial Resupply Services 24 mission. - The space-based research program has generated more than 675 peer-reviewed publications, with over 20% appearing in top-tier journals, underscoring its scientific impact. - Global pharmaceutical companies including Merck & Co., AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sanofi have leveraged microgravity to advance drug discovery, vaccine development, and drug-delivery technologies. - Startups using the ISS National Lab have raised nearly $3 billion in funding after completing their spaceflight projects, highlighting the platform's role as a commercialization incubator.
- GSK's new CEO Luke Miels is executing a three-year, multibillion-dollar restructuring to save roughly $2.5 billion annually ahead of looming patent expirations on blockbuster drugs like dolutegravir. - Novo Nordisk's Maziar Mike Doustdar is working to regain obesity-market momentum lost to Eli Lilly, buoyed by strong uptake of the Wegovy pill despite recent pipeline setbacks. - Sanofi's Dr. Belén Garijo is steering the company toward a post-Dupixent future, with the blockbuster facing loss of exclusivity as soon as 2031. - All three leaders took the helm within the last year at pivotal moments, each aiming to set up the next phase of growth for their companies.
- Manufacturing accounts for roughly 80% of a pharmaceutical company's environmental footprint, making the factory floor the critical intervention point for meaningful change. - Eight leading APAC CDMOs are integrating renewable electricity, water reuse, waste recovery, green chemistry and continuous manufacturing into core production strategy rather than isolated initiatives. - The global sustainable drug manufacturing market is projected to grow from USD 105.8 billion in 2026 to USD 248.2 billion by 2036 at an 8.9% CAGR. - Scope 3 emissions, supplier engagement and internal carbon pricing are emerging as the next frontier, with WuXi AppTec reporting 82.14% of emissions from Scope 3.
- With the CDC largely silent this fall, the American Medical Association and the University of Minnesota's Vaccine Integrity Project published independent reviews in JAMA to guide flu, Covid-19, and RSV immunization. - New recommendations from the AAP, AAFP, ACOG, and IDSA advise RSV immunization for high-risk adults 50+, everyone over 75, pregnant people, and infants, plus annual flu shots for everyone 6 months and older. - Updated Covid-19 vaccines targeting the XFG Omicron subvariant are recommended for adults, with a second dose six months later for those 65 and older, and insurers have indicated coverage without cost sharing. - The first mRNA flu vaccine is newly available for adults 50 and older, while ACOG extended the maternal RSV vaccine window through March 1 due to a later, more severe RSV season.
